5月7日 - ** Iovance Biotherapeutics IOVA.O 股价盘前下跌 8.1%，报 3.76 美元
** 该制药公司报告第一季度总营收为 71.43 7,143万美元，低于 78.40 7,840万美元的预期
** 称收入受其Iovance细胞治疗中心维护工作影响
** 报告称其皮肤癌药物Amtagvi第一季度在美国销售额约为 60 6,000万美元，低于分析师预期的 69.08 6,908万美元
** 预计2026年产品总收入将在3.5亿至3.7亿美元之间；分析师平均预期为3.7048亿美元——数据由LSEG汇编
** 截至2026年3月31日，Iovance的现金储备约为3.19亿美元，预计足以支撑运营至2028年——IOVA
** 截至上一交易日收盘，该股年内累计涨幅达49.8%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.